- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Biological
- Lead sponsor
- Xbrane Biopharma AB
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 8,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hyperlipidemia
- Interventions
- Rosuvastatin, Atorvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 23
- States / cities
- Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- Suicide
- Interventions
- Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement (THRIVE), Center Care as Usual
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Nashville, Tennessee
- Conditions
- Myositis
- Interventions
- Nipocalimab, Placebo, Glucocorticoids
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
- Conditions
- Heart Transplantation
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Oakland, California • San Francisco, California + 7 more
- Conditions
- Type 2 Diabetes
- Interventions
- Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education
- Other
- Lead sponsor
- Biomedical Research Institute of New Mexico
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
- Interventions
- Roflumilast, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 217
- States / cities
- Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
- Conditions
- Open Midline Laparotomy
- Interventions
- Phasix™ Mesh
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 18 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Lp(a) Screening
- Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
- Conditions
- Corneal Edema After Cataract Surgery
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
- Conditions
- Arteriovenous Fistula
- Interventions
- Lutonix DCB, Standard Balloon Angioplasty Catheter, Percutaneous Transluminal Angiography
- Combination Product · Device · Procedure
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 20 more
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2011
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 242
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more
- Conditions
- Staphylococcal Infection
- Interventions
- Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 2,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Preterm Delivery, Preterm Birth
- Interventions
- Fetal Fibronectin, Salivary Estriol
- Device
- Lead sponsor
- Obstetrix Medical Group
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Mesa, Arizona • Phoenix, Arizona
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- inodiftagene vixteplasmid
- Drug
- Lead sponsor
- Anchiano Therapeutics Israel Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Fibrosing Colonopathy
- Interventions
- ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
- Biological · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 0 Months to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
- Conditions
- Urinary Tract Infections
- Interventions
- Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 1,531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Atrial Fibrillation
- Interventions
- Pulse Field Ablation
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Fasiglifam
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 55
- States / cities
- Dothan, Alabama • Muscle Shoals, Alabama • Goodyear, Arizona + 52 more
- Conditions
- Sore Throat, Pharyngitis, Tonsillitis
- Interventions
- APC-111 MP Tablet, 775 mg
- Drug
- Lead sponsor
- Advancis Pharmaceutical Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Tallassee, Alabama • Phoenix, Arizona + 32 more
- Conditions
- Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 214
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more